摘要
患有帕金森病(PD)的患者期待新的治疗策略可能逐渐减缓神经退行性衰退的速度,与行动限制和相关的发病率相关。其持续的神经退行性过程,由基因突变或环境毒素加剧,涉及多巴胺神经传递水平,突触摄取密度,氧化葡萄糖摄入,纹状体乳酸积累不足和慢性炎症的逐渐减少。在过去十年中,新型生物制品因其独特的营养,安全和治疗自然效果的独特潜力而备受关注。一些营养保健品在控制PD中神经传递和炎症中的信号转导途径中起关键作用,并且一些天然化合物可以有益地与这些生物机制中的每一种相互作用以减缓疾病进展。 Atremorine是一种新型植物衍生的营养保健品,可能在黑质多巴胺能神经元(pars compacta)中具有神经保护作用,是这种新型生物制品的原型,对PD有潜在影响。本次评价的主要重点是通过植物衍生的神经保护方法改善PD患者的生活质量,对当前的知识和生物医学调查策略,对于医疗服务提供者,护理人员和患者本身至关重要。
关键词: 帕金森病,多巴胺激动剂,PD动物模型,神经病理学,生物疗法,atremorine
Current Medicinal Chemistry
Title:Dopaminergic Neuroprotection with Atremorine in Parkinson´s Disease
Volume: 25 Issue: 39
关键词: 帕金森病,多巴胺激动剂,PD动物模型,神经病理学,生物疗法,atremorine
摘要: Patients with Parkinson’s disease (PD) are looking forward to new therapeutic strategies that may gradually decelerate the rate of neurodegenerative decline, associated with mobility restrictions and related morbidity. Its continuous neurodegenerative process, exacerbated by genetic mutations or environmental toxins, involves a progressive reduction in the dopamine neurotransmission levels, synaptic uptake density, oxidative glucose intake, deficient striatal lactate accumulation and chronic inflammation. Over the last decade, novel bioproducts have received considerable interest due to their unique potential of unifying nutritional, safety and therapeutic natural effects. Some nutraceuticals play a crucial role in the control of the signaling transduction pathways in neurotransmission and inflammation affected in PD, and some natural compounds can beneficially interact with each one of these biological mechanisms to slow down disease progression. Atremorine, a novel plant-derived nutraceutical, probably with a neuroprotective effect in the dopaminergic neurons of the substantia nigra (pars compacta), is a prototype of this new category of bioproducts with potential effects in PD. The major focus of this review will be on the current knowledge and biomedical investigation strategies through a plant-derived neuroprotective approach to improve life quality in PD patients, being of paramount importance for health providers, caregivers and the patients themselves.
Export Options
About this article
Cite this article as:
Dopaminergic Neuroprotection with Atremorine in Parkinson´s Disease, Current Medicinal Chemistry 2018; 25 (39) . https://dx.doi.org/10.2174/0929867325666180410100559
DOI https://dx.doi.org/10.2174/0929867325666180410100559 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuropharmacology of Cannabinoid System: From Basic Science to Clinical Applications
Current Neuropharmacology The Role of Oxazolidine Derivatives in the Treatment of Infectious and Chronic Diseases
Current Bioactive Compounds Modulation of Matrix Metalloproteinase Activity by Tobacco Cigarette Smoke
Current Chemical Biology Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease
Current Neuropharmacology Evaluation of Pregabalin Therapy in Peripheral Neuropathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Anti-Gene Strategies to Down-Regulate Gene Expression in Mammalian Cells
Current Pharmaceutical Design Acute Myocarditis in Children: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Tuning the Electronic Properties by Width and Length Modifications of Narrow- Diameter Carbon Nanotubes for Nanomedicine
Current Medicinal Chemistry Cisternal Sustained Release Dihydropyridines for Subarachnoid Hemorrhage
Current Neurovascular Research A Dialogue about Protein Crystallization and Phase Diagrams
Protein & Peptide Letters Forced Abstinence Model of Relapse to Study Pharmacological Treatments of Substance Use Disorder
Current Drug Abuse Reviews Management of Impulse Control Disorders with Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Effects of School-Based Physical Activity Interventions on Cognition and Academic Achievement: A Systematic Review
CNS & Neurological Disorders - Drug Targets Is It the Twilight of BACE1 Inhibitors?
Current Neuropharmacology Pathophysiology of Sepsis in the Elderly: Clinical Impact and Therapeutic Considerations
Current Drug Targets Inhibitors of Aldo-Keto Reductases AKR1C1-AKR1C4
Current Medicinal Chemistry Physiological Role of Peroxisome Proliferator-Activated Receptors Type Alpha on Dopamine Systems
CNS & Neurological Disorders - Drug Targets Social Behavior as an Endophenotype for Psychiatric Disorders Development of Mouse Models
Current Genomics Clinical Pharmacology of Serotonin Receptor Type 3 (5-HT3) Antagonists
Current Medicinal Chemistry - Central Nervous System Agents Differential Susceptibility of Naive and Differentiated PC-12 Cells to Methylglyoxal-Induced Apoptosis: Influence of Cellular Redox
Current Neurovascular Research